{"title": "Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management - PubMed", "author": "Username", "url": "https://pubmed.ncbi.nlm.nih.gov/34990422/", "hostname": "ncbi.nlm.nih.gov", "description": "Aunque el tratamiento puede seguir adapt\u00e1ndose a pacientes individuales, se observaron mejores resultados con un enfoque TTM. Conslute Video Resumen en http://links.lww.com/DCR/B708. (Traducci\u00f3n- Dr. Francisco M. Abarca-Rendon).", "sitename": "PubMed", "date": "2022-01-02", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management\n- PMID: 34990422\n-\nDOI:\n[10.1097/DCR.0000000000002281](https://doi.org/10.1097/dcr.0000000000002281)\nAnal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management\nAbstract\nBackground: Anal adenocarcinoma is a rare clinical entity for which the optimal management is not defined.\nObjective: This study aimed to describe the multidisciplinary management and outcomes of patients with anal adenocarcinoma.\nDesign: This is a retrospective cohort study.\nSetting: This study was conducted at a quaternary cancer center.\nPatients: Men and women with anal adenocarcinoma treated between 1995 and 2016 were selected.\nInterventions: Fifty-two patients were treated with either chemoradiotherapy or trimodality therapy including radiation therapy, chemotherapy, and surgical resection.\nMain outcome measures: Local failure, regional failure, and distant metastasis rates were estimated using the cumulative incidence method. The Kaplan-Meier method was used to estimate progression-free survival and overall survival. The multivariable Cox proportional hazards model was used to evaluate the clinical predictors of outcome.\nResults: There was a higher 5-year rate of local failure in patients treated with chemoradiotherapy compared with trimodality therapy (53% vs 10%; p < 0.01). The 5-year incidence of distant metastases was 29% (trimodality therapy) versus 30% (chemoradiotherapy; p = 0.9); adjuvant chemotherapy did not reduce the incidence of distant metastases (p = 0.8). Five-year overall survival was 73% (trimodality therapy) versus 49.4% (chemoradiotherapy; p = 0.1). On multivariable analysis, factors associated with worse overall survival were treatment with chemoradiotherapy, cT3-4 category disease, and node-positive disease.\nLimitations: This study is limited by its small sample size and retrospective nature.\nConclusions: Although treatment may continue to be tailored to individual patients, better outcomes with a trimodality therapy approach were observed. See Video Abstract at http://links.lww.com/DCR/B708.ADENOCARCINOMA ANAL: UNA ENTIDAD POCO FRECUENTE EN NECESIDAD DE UN MANEJO MULTIDISCIPLINARIO.\nAntecedentes: El adenocarcinoma anal es una entidad cl\u00ednica poco frecuente por lo que a\u00fan no se define el manejo \u00f3ptimo.\nObjetivo: Describir el manejo multidisciplinario y los resultados de los pacientes con adenocarcinoma anal.\nDiseo: Estudio de cohorte retrospectivo.\nEntorno clinico: Centro de c\u00e1ncer cuaternario.\nPacientes: Hombres y mujeres con adenocarcinoma anal tratados entre 1995 y 2016.\nIntervenciones: Cincuenta y dos pacientes fueron tratados con quimiorradioterapia o terapia trimodal que incluy\u00f3: radioterapia, quimioterapia y resecci\u00f3n quir\u00fargica.\nPrincipales medidas de valoracion: Se estimaron las tasas de falla local, falla regional y met\u00e1stasis a distancia mediante el m\u00e9todo de incidencia acumulada. Se utiliz\u00f3 el m\u00e9todo de Kaplan-Meier para estimar la supervivencia libre de progresi\u00f3n y la supervivencia global. Los riesgos proporcionales de multivariable Cox se utilizaron para evaluar los predictores cl\u00ednicos de los resultados.\nResultados: Hubo una mayor tasa de falla local a cinco a\u00f1os en pacientes tratados con quimiorradioterapia en comparaci\u00f3n con terapia trimodal (53% vs 10%; p < 0,01). La incidencia a cinco a\u00f1os de met\u00e1stasis a distancia fue del 29% (terapia trimodal) versus 30% (quimiorradioterapia) (p = 0,9); la quimioterapia adyuvante no redujo la incidencia de met\u00e1stasis a distancia (p = 0,8). La supervivencia global a cinco a\u00f1os fue del 73% (terapia trimodal) versus 49,4% (quimiorradioterapia); p = 0,1. En el an\u00e1lisis multivariable, los factores asociados con una peor supervivencia general fueron el tratamiento con quimiorradioterapia, enfermedad de categor\u00eda cT3-4 y enfermedad con ganglios positivos.\nLimitaciones: Este estudio est\u00e1 limitado por su peque\u00f1o tama\u00f1o de muestra y su naturaleza retrospectiva.\nConclusiones: Aunque el tratamiento puede seguir adapt\u00e1ndose a pacientes individuales, se observaron mejores resultados con un enfoque TTM. Conslute Video Resumen en http://links.lww.com/DCR/B708. (Traducci\u00f3n- Dr. Francisco M. Abarca-Rendon).\nCopyright \u00a9 The ASCRS 2021.\nSimilar articles\n-\n[Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy.](/34990423/)Dis Colon Rectum. 2022 Feb 1;65(2):198-206. doi: 10.1097/DCR.0000000000001997. Dis Colon Rectum. 2022. PMID: 34990423\n-\n[Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.](/34775415/)Dis Colon Rectum. 2022 Mar 1;65(3):333-339. doi: 10.1097/DCR.0000000000002197. Dis Colon Rectum. 2022. PMID: 34775415\n-\n[Effects of Adjuvant Therapy Compliance and Anastomotic Leakage on the Oncologic Outcomes of Patients With Rectal Cancer After Curative Resection.](/33394777/)Dis Colon Rectum. 2021 Jun 1;64(6):689-696. doi: 10.1097/DCR.0000000000001824. Dis Colon Rectum. 2021. PMID: 33394777 Free PMC article.\n-\n[Neoadjuvant Therapy in Stage II/III Rectal Cancer: A Retrospective Study in a Disparate Population and the Effect on Survival.](/34516443/)Dis Colon Rectum. 2021 Oct 1;64(10):1212-1221. doi: 10.1097/DCR.0000000000001977. Dis Colon Rectum. 2021. PMID: 34516443 Review.\n-\n[[Hidrocefalia cong\u00e9nita-neonatal: alternativas terap\u00e9uticas a la derivaci\u00f3n. Una mirada a la terapia celular].](/30361715/)Cir Cir. 2018;86(6):575-582. doi: 10.24875/CIRU.18000054. Cir Cir. 2018. PMID: 30361715 Review. Spanish.\nCited by\n-\n[Survival outcomes of anal adenocarcinoma versus rectal adenocarcinoma: A retrospective cohort study.](/37648878/)Indian J Gastroenterol. 2023 Aug 31. doi: 10.1007/s12664-023-01394-0. Online ahead of print. Indian J Gastroenterol. 2023. PMID: 37648878\nReferences\n-\n- Cabrera A, Tsukada Y, Pickren JW. Adenocarcinomas of the anal canal and peri-anal tissues. Ann Surg. 1966;164:152\u2013156.\n-\n- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.\n-\n- Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27\u201333.\n-\n- Hosni A, Han K, Le LW, et al. The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. Oncotarget. 2018;9:20439\u201320450.\n-\n- Belkac\u00e9mi Y, Berger C, Poortmans P, et al.; Rare Cancer Network. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2003;56:1274\u20131283.\nMeSH terms\nSubstances\nLinkOut - more resources\nFull Text Sources\nMedical\nResearch Materials", "language": null, "image": "https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png", "pagetype": "website", "links": ["#article-details", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", null, "/", "#", "#", "/advanced/", "/clipboard/", "/help/", "#", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34990422%2F%23open-bibliography-panel", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34990422%2F%23open-collections-panel", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/account/settings/", "https://doi.org/10.1097/DCR.0000000000002281", "#", "#", "http://twitter.com/intent/tweet?text=Anal%20Adenocarcinoma%3A%20A%20Rare%20Entity%20in%20Need%20of%20Multidisciplinary%20Management%20https%3A//pubmed.ncbi.nlm.nih.gov/34990422/", "http://www.facebook.com/sharer/sharer.php?u=https%3A//pubmed.ncbi.nlm.nih.gov/34990422/", "#heading", "#abstract", "#similar", "#citedby", "#references", "#mesh-terms", "#substances", "#related-links", "#linkout", "/?term=%22Dis+Colon+Rectum%22%5Bjour%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Dis+Colon+Rectum%22%5BTitle+Abbreviation%5D", "#", "/?term=Lukovic+J&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Kim+JJ&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Liu+ZA&cauthor_id=34990422", "#full-view-affiliation-3", "/?term=Cummings+BJ&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Brierley+JD&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Wong+RKS&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Ringash+JG&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Dawson+LA&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Barry+A&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "/?term=Krzyzanowska+MK&cauthor_id=34990422", "#full-view-affiliation-4", "/?term=Chen+EX&cauthor_id=34990422", "#full-view-affiliation-4", "/?term=Hedley+DW&cauthor_id=34990422", "#full-view-affiliation-4", "/?term=Quereshy+FA&cauthor_id=34990422", "#full-view-affiliation-5", "/?term=Swallow+CJ&cauthor_id=34990422", "#full-view-affiliation-5", "#full-view-affiliation-6", "/?term=Gryfe+RN&cauthor_id=34990422", "#full-view-affiliation-5", "#full-view-affiliation-6", "/?term=Kennedy+ED&cauthor_id=34990422", "#full-view-affiliation-5", "#full-view-affiliation-6", "/?term=Easson+AM&cauthor_id=34990422", "#full-view-affiliation-5", "#full-view-affiliation-6", "/?term=Hosni+A&cauthor_id=34990422", "#full-view-affiliation-1", "#full-view-affiliation-2", "https://doi.org/10.1097/dcr.0000000000002281", "/?term=%22Dis+Colon+Rectum%22%5Bjour%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Dis+Colon+Rectum%22%5BTitle+Abbreviation%5D", "#", "/?term=Lukovic+J&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Kim+JJ&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Liu+ZA&cauthor_id=34990422", "#short-view-affiliation-3", "/?term=Cummings+BJ&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Brierley+JD&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Wong+RKS&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Ringash+JG&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Dawson+LA&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Barry+A&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "/?term=Krzyzanowska+MK&cauthor_id=34990422", "#short-view-affiliation-4", "/?term=Chen+EX&cauthor_id=34990422", "#short-view-affiliation-4", "/?term=Hedley+DW&cauthor_id=34990422", "#short-view-affiliation-4", "/?term=Quereshy+FA&cauthor_id=34990422", "#short-view-affiliation-5", "/?term=Swallow+CJ&cauthor_id=34990422", "#short-view-affiliation-5", "#short-view-affiliation-6", "/?term=Gryfe+RN&cauthor_id=34990422", "#short-view-affiliation-5", "#short-view-affiliation-6", "/?term=Kennedy+ED&cauthor_id=34990422", "#short-view-affiliation-5", "#short-view-affiliation-6", "/?term=Easson+AM&cauthor_id=34990422", "#short-view-affiliation-5", "#short-view-affiliation-6", "/?term=Hosni+A&cauthor_id=34990422", "#short-view-affiliation-1", "#short-view-affiliation-2", "https://doi.org/10.1097/dcr.0000000000002281", "/34990423/", "/34775415/", "/33394777/", "/34516443/", "/30361715/", null, "/37648878/", "/?term=%22Adenocarcinoma%2Fdiagnosis%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Adenocarcinoma", "#", "/?term=%22Adenocarcinoma%2Fmortality%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Adenocarcinoma", "#", "/?term=%22Adenocarcinoma%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Adenocarcinoma", "#", "/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Adult", "#", "/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Aged", "#", "/?term=%22Antineoplastic+Agents%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents", "#", "/?term=%22Anus+Neoplasms%2Fdiagnosis%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Anus+Neoplasms", "#", "/?term=%22Anus+Neoplasms%2Fmortality%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Anus+Neoplasms", "#", "/?term=%22Anus+Neoplasms%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Anus+Neoplasms", "#", "/?term=%22Combined+Modality+Therapy%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Combined+Modality+Therapy", "#", "/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Female", "#", "/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Humans", "#", "/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Male", "#", "/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged", "#", "/?term=%22Practice+Patterns%2C+Physicians%27%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Practice+Patterns%2C+Physicians%27", "#", "/?term=%22Proctectomy%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Proctectomy", "#", "/?term=%22Retrospective+Studies%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Retrospective+Studies", "#", "/?term=%22Survival+Rate%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Survival+Rate", "#", "/?term=%22Treatment+Outcome%22%5BMeSH%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=Treatment+Outcome", "#", "/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc", "https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22", "#", "https://www.ncbi.nlm.nih.gov/medgen/?linkname=pubmed_medgen&from_uid=34990422", "https://www.ingentaconnect.com/openurl?genre=article&issn=&volume=65&issue=2&spage=189&aulast=Lukovic", "http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=34990422.ui", "https://doi.org/10.1097/DCR.0000000000002281", "https://ClinicalTrials.gov/search/term=34990422%20%5BPUBMED-IDS%5D", "https://medlineplus.gov/analcancer.html", "https://antibodies.cancer.gov/detail/CPTC-NT5E-1", "https://doi.org/10.1097/DCR.0000000000002281", "#", "#", "#", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34990422%2F%23open-bibliography-panel", "https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34990422%2F%23open-collections-panel", "#", "https://www.ncbi.nlm.nih.gov/mesh/", "https://www.ncbi.nlm.nih.gov/pmc/", "https://www.ncbi.nlm.nih.gov/books", "/disclaimer/", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}